Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Katherine Holden Rinard

Urology Abilene, TX Medical Doctor

NPI 1225299795 CMS profile 282181

1924 Pine St, Suite 505, Abilene, TX 79601

Open in the dashboard

General payments

$4,491

94 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Holden Rinard of Abilene, TX is reported in the CMS Open Payments database as having received $4,491 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $573 10
2024 General $83 4
2023 General $421 9
2022 General $1,625 21
2021 General $140 5
2020 General $189 8
2019 General $1,462 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Holden Rinard
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Katherine Holden Rinard were reported at $573. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Katherine Holden Rinard Urology median Middle half National median
2019 $1,462 $480 $147–$1,201 $163
2020 $189 $246 $87–$645 $114
2021 $140 $358 $111–$1,000 $132
2022 $1,625 $476 $143–$1,263 $149
2023 $421 $560 $168–$1,461 $160
2024 $83 $563 $170–$1,464 $164
2025 $573 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,839 24 payments
  2. PROCEPT BioRobotics Corporation $606 8 payments
  3. Intuitive Surgical, Inc. $590 2 payments
  4. Photocure Inc $236 4 payments
  5. Medtronic USA, Inc. $211 11 payments
  6. Astellas Pharma US Inc $185 10 payments
  7. NeoTract Inc. $110 4 payments
  8. Cook Medical LLC $104 2 payments
  9. Teleflex LLC $100 3 payments
  10. Boston Scientific Corporation $99 6 payments
  11. Other $412 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,017 87 payments
  2. Travel and Lodging $1,475 7 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $1,839 24 payments
  2. Da Vinci Surgical System $590 2 payments
  3. AQUABEAM ROBOTIC SYSTEM Urology $423 6 payments
  4. Cysview $236 4 payments
  5. INTERSTIM Sacral Nerve Stimulation $211 11 payments
  6. MYRBETRIQ $185 10 payments
  7. AQUABEAM ROBOTIC SYSTEM Urology $183 2 payments
  8. UROLIFT $110 4 payments
  9. Cook Medical Extractors $89 1 payment
  10. UroLift System $71 2 payments
  11. Other $580 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,065

Median for Urology: 1,053

Drug cost

$142,828

Median for Urology: $101,464

Branded share of claims

40.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 114 $80,383
Myrbetriq Mirabegron Brand 57 $36,158
Estradiol Generic 160 $10,639
Potassium Citrate Er Potassium Citrate Brand 79 $6,115
Tamsulosin Hcl Generic 265 $4,421
Oxybutynin Chloride Er Oxybutynin Chloride Brand 100 $1,758
Tolterodine Tartrate Er Tolterodine Tartrate Brand 15 $1,382
Finasteride Generic 79 $1,022
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 33 $441
Cephalexin Generic 57 $183

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$137,901

Medicare's payments for the services billed

Medicare patients

510

Average age 75

Services billed

1,712

269 women, 241 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Ischemic heart disease 41%
Diabetes 34%
Chronic kidney disease 33%
Atrial fibrillation 28%
Depression 28%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record